Mehra Golshan
Yale University
196 Papers
737 Citations
Mehra Golshan is an academic researcher from Yale University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 39, co-authored 186 publications. Previous affiliations of Mehra Golshan include Northwestern University & University of Illinois at Chicago.
Chat about Author
Papers
Surgery of the primary tumor does not improve survival in stage IV breast cancer.
Laura S. Dominici,Laura S. Dominici,Julie Najita,Melissa E. Hughes,Joyce C. Niland,Paul K. Marcom,Yu-Ning Wong,Bradford Carter,Sara H. Javid,Stephen B. Edge,Harold J. Burstein,Mehra Golshan,Mehra Golshan +12 more
TL;DR: Surgery was not shown to improve survival in the stage IV setting for this subset of metastatic breast cancer patients, when matching for the variables associated with a survival benefit in previous studies.
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Mehra Golshan,Constance Cirrincione,William M. Sikov,Lisa A. Carey,Donald A. Berry,Beth Overmoyer,Nora Lynn Henry,George Somlo,Elisa Port,Harold J. Burstein,Clifford A. Hudis,Eric P. Winer,David W. Ollila +12 more
TL;DR: Many patients with HER2 + BC deemed ineligible for BCT at baseline can be converted to BCT-eligible with NST; excluding patients with multicentric disease substantially increases that percentage.
Great Debate: The Surgeon’s Role in Locoregional Management of Stage IV Breast Cancer
TL;DR: This research presents a novel and scalable approach called “cell reprograming” that allows for real-time, 3-D image analysis of the lesion progression in women undergoing surgery for breast cancer treatment.
Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis
David Calligaris,Diana Caragacianu,Xiaohui Liu,Isaiah Norton,Christopher J. Thompson,Andrea L. Richardson,Andrea L. Richardson,Mehra Golshan,Michael L. Easterling,Sandro Santagata,Sandro Santagata,Deborah A. Dillon,Ferenc A. Jolesz,Nathalie Y. R. Agar +13 more
TL;DR: It is shown that tumor margins can be identified using the spatial distributions and varying intensities of different lipids, and an MS-based method could be developed for the rapid intraoperative detection of residual cancer tissue during breast-conserving surgery.
CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).
William M. Sikov,Mei Yin C. Polley,Erin Twohy,Charles M. Perou,Baljit Singh,Donald A. Berry,Sara M. Tolaney,George Somlo,Elisa R. Port,Cynthia X. Ma,Charles S. Kuzma,Eleftherios P. Mamounas,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Lisa A. Carey +19 more
TL;DR: CALGB 40603 is a 2x2 randomized trial that previously demonstrated that adding Cb to NACT signified activity when combined with standard chemotherapy in TNBC.